ClinicalTrials.gg
RecruitingNCT07540403EPOCAUpdated Apr 20, 2026

Survival Analysis in patiEnts With Bad Prognosis Epithelial Ovarian CArcinoma

An observational study in Ovarian Cancer, sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. Recruiting at 1 site in Italy. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-20.

Sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Observational

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
50
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Ovarian Neoplasms by Fondazione Policlinico Universitario Agostino Gemelli IRCCS — 28 open to participants now, 32 under way, none of them phase 3. Ovarian Neoplasms · Fondazione Policlinico Universitario Agostino Gemelli IRCCS.

Planned enrollment
15th of 22
50 · median 160
Started
2025
with 7 others
Observational
22 of 40
19 open now
Primary completion
2027-03
later than 25 of 31 live
Registered
25th of 40
by date

Among the 40 studies in Ovarian Neoplasms by Fondazione Policlinico Universitario Agostino Gemelli IRCCS, this one is the 15th largest by planned enrollment of the 22 observational ones that give a count, is one of 8 that started in 2025, is one of 22 observational ones, reaches primary completion later than 25 of the 31 other live ones, and was the 25th registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

28 of the 40 studies in Ovarian Neoplasms by Fondazione Policlinico Universitario Agostino Gemelli IRCCS are open now, in 1 country. Recruiting first, the newest first:

22 more — sign in →

By country, each count listing its studies:

All 28 open studies →

Where they have run

Who these studies take

Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Ovarian Neoplasms by Fondazione Policlinico Universitario Agostino Gemelli IRCCS, or all of them as a file.
02

Study summary

Ovarian carcinoma is the most lethal gynecological malignancy. Epithelial ovarian carcinoma is the gynecological malignancy with the highest mortality rate. The prognosis of patients with recurrent disease is highly heterogeneous and is typically poor in cases of ovarian carcinoma with a progression-free survival (PFS) ≤ 6 months, for which therapeutic options are limited. However, it has been shown that patients with a PFS ≤ 6 months may not respond effectively to further treatments, whereas, conversely, patients with a PFS > 6 months could still benefit from them.

The classification of patients with recurrent disease has undergone continuous evolution over time. Essential factors to consider include patient characteristics, disease stage, and the precise genetic and molecular profile of the tumor. This study aims to evaluate survival in patients experiencing recurrence of epithelial ovarian carcinoma with an unfavorable prognosis, with the objective of improving patient categorization and management.

Read the detailed description

The study is a collection of clinical-pathological and prognostic data from patients with recurrent epithelial ovarian carcinoma with a progression-free survival of ≤ 6 months.

All patients, identified consecutively, will be registered by the investigators, after verification of the eligibility criteria.

The requested data will be recorded in a specific anonymous database. The physician will be asked to complete all the database entries that will be analyzed to evaluate the primary and secondary endpoints.

03

Conditions studied

  • Ovarian Cancer

Keywords

  • ovarian cancer
  • platinum-resistance
  • recurrence
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients with Ovarian Cancer with PFS ≤6 months meeting the inclusion criteria and whose diagnostic-therapeutic pathway took place between January 2017 and December 2023 will be included.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with confirmed epithelial ovarian carcinoma, fallopian tube carcinoma, or primary peritoneal carcinoma with a PFS ≤6 months.

    • Age ≥18 years.
    • Any FIGO (Federation of Gynecology and Obstetrics) stage at diagnosis.
    • Signed for the use of personal data for research purposes.
    • performance status ≤2.

Exclusion criteria

  • Age \<18 years.

    • Patients with non-epithelial ovarian carcinoma.
    • Patients with a PFS >6 months.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
50 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes

Groups and cohorts

  • platinum-resistant recurrence

    All patients will be trated according to standard practice

06

What researchers measure

Primary outcomes

  1. Characteristic 1 of patients

    Weight (Kg) expressed as mean and standard deviation or median and interquartile range, as appropriate.

    Time frame: 2 years

  2. Characteristic 2 of patients

    Height (cm) expressed as mean and standard deviation or median and interquartile range, as appropriate.

    Time frame: 2 years

  3. Characteristic 3 of patients

    Age (years) expressed as mean and standard deviation or median and interquartile range, as appropriate.

    Time frame: 2 years

  4. Characteristic 4 of patients

    ca 125 levels (U/mL) expressed as mean and standard deviation or median and interquartile range, as appropriate.

    Time frame: 2 years

  5. Characteristic 5 of patients

    Tumor stage (1-2-3-4) expressed as absolute and percentage frequency.

    Time frame: 2 years

  6. Characteristic 6 of patients

    histotype (HGSOC, LGSOC, HG endometrioid, LG endometrioid, clear cell, other) expressed as absolute and percentage frequency.

    Time frame: 2 years

  7. Characteristic 7 of patients

    molecular profiling (HRD positive, HRD negative) expressed as absolute and percentage frequency.

    Time frame: 2 years

  8. Characteristic 8 of patients

    mutation of BRCA ½ (mutation, wild type) expressed as absolute and percentage frequency.

    Time frame: 2 years

Secondary outcomes

  1. Survival data

    Progression free survival and Overall survival in months.

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Davis A, Tinker AV, Friedlander M. "Platinum resistant" ovarian cancer: what is it, who to treat and how to measure benefit? Gynecol Oncol. 2014 Jun;133(3):624-31. doi: 10.1016/j.ygyno.2014.02.038. Epub 2014 Mar 4. PubMed 24607285 ↗
  • Wilson MK, Pujade-Lauraine E, Aoki D, Mirza MR, Lorusso D, Oza AM, du Bois A, Vergote I, Reuss A, Bacon M, Friedlander M, Gallardo-Rincon D, Joly F, Chang SJ, Ferrero AM, Edmondson RJ, Wimberger P, Maenpaa J, Gaffney D, Zang R, Okamoto A, Stuart G, Ochiai K; participants of the Fifth Ovarian Cancer Consensus Conference. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease. Ann Oncol. 2017 Apr 1;28(4):727-732. doi: 10.1093/annonc/mdw663. PubMed 27993805 ↗
  • Pignata S, C Cecere S, Du Bois A, Harter P, Heitz F. Treatment of recurrent ovarian cancer. Ann Oncol. 2017 Nov 1;28(suppl_8):viii51-viii56. doi: 10.1093/annonc/mdx441. PubMed 29232464 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Mar 2027, 23 months after the start.

Of 216 non-industry observational studies under Ovarian Neoplasms, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 206. This study's planned 23 months is below that.

Counting every sponsor, half of 268 studies reached it within 61 months; a quarter within 35 and three quarters within 185.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2025
First posted
Apr 20, 2026
StartActual
Mar 24, 2025
Primary completionEst.
Mar 1, 2027
CompletionEst.
Mar 1, 2027
Last update
Apr 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07540403
Responsible party
MARCHETTI CLAUDIA (Associate Professor, Fondazione Policlinico Universitario Agostino Gemelli IRCCS) — Principal investigator
First posted
Apr 20, 2026
Start date
Mar 24, 2025
Primary completion
Mar 1, 2027 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Apr 20, 2026

Study contacts

Claudia Marchetti
Contact
claudia.marchetti@policlinicogemelli.it
00393935860248
Claudia Marchetti
principal investigator · Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion